Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.

Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2019 Jan;17(1):12-20. doi: 10.6004/jnccn.2019.0002.

PMID:
30659125
2.

Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphoma.

Vachhani P, Neppalli VT, Cancino CJ, Bogner P, Roche CL, Paragh G, Grassi MA, Hernandez-Ilizaliturri FJ.

Br J Haematol. 2019 Feb;184(4):674-676. doi: 10.1111/bjh.15154. Epub 2018 Feb 22. No abstract available.

PMID:
29468663
3.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

PMID:
29295877
4.

Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era.

Morton LM, Cerhan JR, Hartge P, Vasef MA, Neppalli VT, Natkunam Y, Dogan A, Dave BJ, Jain S, Levy R, Lossos IS, Cozen W, Davis S, Schenk MJ, Maurer MJ, Lynch CF, Rothman N, Chatterjee N, Yu K, Staudt LM, Weisenburger DD, Wang SS.

Int J Mol Epidemiol Genet. 2011 Aug 30;2(3):245-52. Epub 2011 Jul 5.

5.

Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.

Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van Ness B, Janz S.

Clin Cancer Res. 2011 Dec 1;17(23):7313-23. doi: 10.1158/1078-0432.CCR-11-0636. Epub 2011 Sep 8.

6.

Reappraisal of the provisional entity primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma: a series of 10 adult and pediatric patients and review of the literature.

Baum CL, Link BK, Neppalli VT, Swick BL, Liu V.

J Am Acad Dermatol. 2011 Oct;65(4):739-748. doi: 10.1016/j.jaad.2010.07.028. Epub 2011 Jun 8.

PMID:
21641676
7.

Dextran removal by plasmapheresis in a kidney-pancreas transplant recipient with dextran 40-induced osmotic nephrosis.

Bhatt AP, Neppalli VT, Kelley EA, Schlueter AJ, Thomas CP.

Am J Kidney Dis. 2011 Apr;57(4):621-3. doi: 10.1053/j.ajkd.2010.10.057. Epub 2011 Jan 22.

PMID:
21257240
8.

IL-6 and MYC collaborate in plasma cell tumor formation in mice.

Rutsch S, Neppalli VT, Shin DM, DuBois W, Morse HC 3rd, Goldschmidt H, Janz S.

Blood. 2010 Mar 4;115(9):1746-54. doi: 10.1182/blood-2009-08-237941. Epub 2009 Dec 17.

9.

BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.

Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, Lynch J, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Campo E, Ott G, Müller-Hermelink HK, Delabie J, Jaffe ES, Grogan TM, Connors JM, Vose JM, Armitage JO, Staudt LM, Chan WC.

J Clin Oncol. 2006 Feb 20;24(6):961-8. Epub 2006 Jan 17.

PMID:
16418494

Supplemental Content

Loading ...
Support Center